Abstract 782P
Background
CRS after neoadjuvant chemotherapy (NACT) and gBRCA status predict survival outcomes of women diagnosed with advanced HGSOC. We investigated the correlation between CRS and gBRCA to understand the potential of CRS as an inexpensive biomarker for PARPi therapy.
Methods
Analysis of the OC gBRCA testing database from a tertiary referral centre. Eligible criteria included women with FIGO stage IIIC/IV HGSOC who received NACT and had gBRCA tested between 01/09/2017 and 31/12/2022. Univariable and Multivariable (MV) Cox Proportional-Hazards Models were applied to assess the association between PFS, OS and clinical factors. Two-Proportions Z Test was applied to assess the proportions of CRS1+2 or CRS3 between gBRCA.
Results
536 women were eligible. Mean age 66 years (range 36–89). 139 had FIGO stage IVB HGSOC. 71% received 3-weekly carboplatin with paclitaxel. Median PFS was 14.4 months (95%CI 13.6–15.4) and OS 38.0 months (95%CI 34.8–42.6) in the overall population. Performance status (0–1 vs. 2–4), cytoreductive surgery (Yes vs. No) and gBRCA status (mutant[MT] vs. wild type[WT]) were predictive (PFS) and prognostic (OS) in the overall population (all P<0.05). 363 women underwent delayed primary surgery (DPS) and had a CRS. Of these, 90% received 3–4 cycles of NACT and 96% had optimal (≤1 cm) cytoreduction. In the NACT-DPS group, MV analysis showed that residual disease (≤1 vs. >1 cm), CRS (3 vs. 1+2) and gBRCA status (MT vs. WT) were predictive (PFS) (all P≤0.02). Proportion testing showed women with gBRCA2 were more likely to have CRS3 vs. CRS1+2 than those with gBRCA1 (P=0.008). Women with gBRCA1 (P=0.075) and gBRCA2 (P=0.078) were not more likely to have CRS3 vs. CRS1+2 then those with WT.
Conclusions
We found a correlation between CRS3 and gBRCA2, but not gBRCA1, in women with FIGO stage IIIC/IV HGSOC treated with NACT-DPS. CRS should be evaluated in a prospective study as a predictor of PARPi efficacy.
Table: 782P
CRS | gBRCA1 | gBRCA2 | WT | PFS, months (95%CI) |
1 | 7 | 1 | 60 | 12.1 (11.5–15.7) |
2 | 19 | 9 | 146 | 15.4 (14.4–16.7) |
1+2 | 26 (84%) | 10 (45%) | 206 (66%) | 14.9 (14.0–16.0) |
3 | 5 (16%) | 12 (55%) | 104 (34%) | 22.8 (20.7–27.9) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R.D. Morgan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11